​Anxiety and Mood Disorder Center

 Some Completed Clinical studies

A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety and Tolerability of JNJ-42165279 in Subjects with Social Anxiety Disorder. Principal Investigator September 2017 to May 2018.

A Phase 2a Randomized, Double-blind, Placebo-controlled, Parallel-Group, Multi-center study investigating the Efficacy, Safety and Tolerability of JNJ-42165279 in subjects with Social Anxiety Disorder. Principal Investigator June 1, 2015 to February 2016

Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-4 Study) Principle Investigator April 2014 – March 2015.

Shire 489-346 A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years with Moderate to Severe Binge Eating Disorder.  Principle Investigator December 2013 – March 2014

Efficacy and safety of agomelatine (25mg/day with blinded potential adjustment to 50mg/day) versus escitalopram (10mg/day with blinded potential adjustment to 20mg/day) given orally for 12 weeks in non-depressed outpatients with severe Generalized Anxiety Disorder.

A 12 week randomized, double-blind, versus escitalopram, 2-arm parallel groups, international multicenter study with a 9 month extension period. Principle Investigator. April 3, 2013 to April 8, 2015.

Effects of agomelatine versus escitalopram on emotional experiences in outpatients suffering from Major Depressive Disorder.  An exploratory, randomized, double-blind, international, multicentre study with parallel groups: agomelatine (25 to 50 mg/day) versus escitalopram (10 to 20 mg/day) over a 6-month period.  Prinicpal Investigator - June 2012 to April 8, 2015.

The SPD489-322 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination with an Antidepressant in the Treatment of Adults with Major Depressive Disorder with Inadequate Response to Prospective Treatment with an Antidepressant.  Principal Investigator – December 2011

Pipamperone/Citalopram (PNB01) versus Citalopram (CIT) and versus Pipamperone (PIP)  in moderate to severe Major Depressive Disorder (MDD): a randomized, double-blind phase III clinical trial of 10 weeks.  Principal Investigator - December 20, 2011.

Randomised, double-blind, parallel-group, placebo-controlled, fixed dose study on the efficacy of Lu AA21004 on cognitive dysfunction in adult patients with Major Depressive Disorder (MDD). H. Lundbeck A/S 14122A. Principal Investigator - November 2011.

A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to evaluate the efficacy and safety of Armodafinil Treatment (150 and 200mg/day) as Adjunctive Therapy in Adults with Major Depression Associated with Bipolar I Disorder.  Cephalon Inc. C10953/3071/3074Principal Investigator.  January 2011

Efficacy and safety of 3 doses (0.25, 0.5 and 1mg/day) of agomelatine sublingual administration over an 8-week treatment period, in out-patients with Major Depressive Disorder.  An 8-week randomized, double blind, fixed dose, international multicentre, placebo-controlled study with parallel groups, followed by an extension double-blind treatment period of 16 weeks. Servier CL2-90098-009 Principal Investigator. January 2010 to Nov 2010.

A Randomised, double-blind, placebo controlled study evaluating the efficacy and safety of Orvepitant in subjects with major depressive disorder.  GW823296 – GSK-NKG110833 February 2009 to February 2010.

“An Evaluation of efficacy and clinical benefit of agomelatine (25-50 mg/day) over a 6 month treatment period in patients with major depressive disorder”. Servier 062 Principal Investigator, April 2009.

“A randomized, double-bline, parallel-group, placebo-controlled, duloxetine-referenced, dose-finding study of Lu AA24530 in major depressive disorder”. Principal Investigator, August 2008 – June 2009.

“A 6 week randomized double-blind, placebo-controlled study of BCI-540 80 mgqd and 80 mgtid in the treatment of adults with major depressive disorder and concomitant anxiety”. Principal Investigator, July 2008 to July 2009.

“Attributes of response in depressed patients switched treatment with Duloxetine (ARDENT Study)”. Principal Investigator, July 2008 to May 2009.

“A multi-center ramdomized, placebo-controlled, double-blind, parallel group, Phase IIb proof of concept study with 3 oral dose groups of AZD3480 during 12 weeks treatment of cognitive deficits in patients with schizophrenia”. HALO. Principal Investigator, March 2008 to September 2008.

“Efficacy of agomelatine (25 to 50mg/day) given orally on improvement of subjective sleep in patients with Major Depressive Disorder”.  A randomized, double-blind, flexible-dose international multicentre study with parallel groups versus escitalopram (10 to 20mg/day). Servier 063. Principal Investigator. October 2007 to February 2008.

“Efficacy and safety of agomelatine (25mg-50mg) given orally compared to placebo in addition to a moood stabilize in Bipolar I patients with a current major depressive episode”.  An 8 wk randomized, double-blind extension treatment period up to 1 year. Servier 047. Principal Investigator, January 2007 to April 2008. 

“A 10 wk multi-centre randomized double-blind placebo and active, controlled. Parallel group GSK372475 or paroxetine compared to placebo in a subject diagnosed with major depression disorder”. Principal Investigator, January 2007 to June 2008.

“12 wk flexible dose study of GW876008, Esquivel, and active control [paroxetine] in the treatment of Social Anxiety Disorder”. Principal Investigator, November 2006 to September 2007.

A Multi-centre, Double-blind, Randomised-withdrawal, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR) as Monotherapy in the Maintenance Treatment of Patients with Major Depressive Disorder Following an Open-Label Stabilization Period”. Principal Investigator, April 2006 – October 2006

“A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Evaluating the Efficacy and Safety of GW679769 in Subjects with Major Depressive Disorder” Principal Investigator, February 2006–May 2006

“Safety and efficacy of Quetiapine fumerate as Monotherapy in continuation treatment for Adult patient with Bipolar Depression” for 20 up to 52 weeks in comparison with placebo and lithium “, Principal Investigator, October 2005-December 2006.

An International Multicenter, Double-Blind , Randomised, Parallel-group, Placebo-controlled, Phase 111 Study of the efficacy and safety of Quetiapine fumerate and lithium as monotherapy for 8 weeks of treatment in Adult Patients with Bipolar Depression". Principal Investigator, October 2005-2006.

A Multicenter, Randomized, Double-Blind, Parallel Study to evaluate the safety and efficacy of flexible dose of Lamotrigine compared to placebo as an adjunctive therapy to an Atypical antipsychotic agent in subject with schizophrenia." Principal Investigator, December 2004- June 2005.

Fluoxetine - olanzapine in the treatment of refractory depression".    Principal Investigator, July 2004-2005.

The effect of an 8 week intensive cognitive therapy day program on the level of function in patients with chronic mental illness". Principal Investigator, 2002-2003.

HOCCC outcome study for patient with chronic Mental illness”. Principal Investigator December 2002- 2004.

Robalzotan, Paroxetine, double blind placebo control" research protocol, Principal Investigator, March 2001- December 2001

S.T.A.M.I.N.A" study, Quitiapine + mood stabilizer vs. placebo + mood stabilizer in patient with Mania”. Co-investigator, 2000-2001.

Reboxetine, Paroxetine, double blind placebo control” research protocol. Principal Investigator, May 2000- December 2001.

Reboxetine continuation study”, Principal Investigator, August 15th 2000 – December 2001.

Efficacy of group cognitive therapy as a treatment modality among patient with social anxiety disorders", Outcome study - Principal Investigator, The Credit Valley Hospital 1995.

Efficacy of group cognitive therapy as a treatment modality among patient with panic disorders". Outcome study, Principal Investigator, The Credit Valley Hospital 1994.

Bromocriptine vs. placebo augmentation in treatment refractory patients” research protocol, Principal Investigator, 1988.

Brofaramine double blind placebo control". Dr. Sid Kennedy principal investigator, 1988

Adenazolam, desipramine double blind placebo control "Dr. Sid Kennedy, Principal investigator, 1988.